Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer

Windy Olaya, Jan Wong, John W. Morgan, Caitlyn Truong, Sharmila Roy-Chowdhury, Kevork Kazanjian, Sharon Lum

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Guidelines recommend sentinel lymph node dissection (SLND) for patients with clinical stage I/IIA/IIB breast cancer; however, a significant fraction of patients do not undergo this procedure. We sought to identify factors associated with noncompliance with the SLND benchmark in early-stage breast cancer. Materials and Methods: All patients with an initial diagnosis of Stage I/IIA/IIB invasive breast carcinoma who were treated between 2004 and 2007 with records in the California Cancer Registry were evaluated. Odds ratios evaluating receipt of SLND were compared for sex, age, stage, socioeconomic status (SES), race/ethnicity, surgery type, year of diagnosis, and hospital cancer program approval from the American College of Surgery (ACOS). Results: Of 55,207 patients identified, 66% underwent SLND. On multivariable analyses, patients were significantly less likely to undergo SLND if they were >65 years of age, stage IIA or IIB, of lower socioeconomic status, of nonwhite race/ethnicity, treated with total mastectomy, treated during 2004-2005, or at a non-ACOS approved institution. Conclusions: SLND use in California has increased over time; however, only two-thirds of eligible patients undergo this recommended procedure. Using SLND as a quality measure demonstrates significant disparities that have implications not only for patient and provider education, but also for health care policy and reform.

Original languageEnglish (US)
JournalAnnals of Surgical Oncology
Volume17
Issue numberSUPPL. 3
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Lymph Node Excision
Breast Neoplasms
Social Class
Simple Mastectomy
Cancer Care Facilities
Benchmarking
Health Care Reform
Patient Education
Health Policy
Sentinel Lymph Node
Registries
Odds Ratio
Guidelines
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer. / Olaya, Windy; Wong, Jan; Morgan, John W.; Truong, Caitlyn; Roy-Chowdhury, Sharmila; Kazanjian, Kevork; Lum, Sharon.

In: Annals of Surgical Oncology, Vol. 17, No. SUPPL. 3, 10.2010.

Research output: Contribution to journalArticle

Olaya, Windy ; Wong, Jan ; Morgan, John W. ; Truong, Caitlyn ; Roy-Chowdhury, Sharmila ; Kazanjian, Kevork ; Lum, Sharon. / Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. SUPPL. 3.
@article{b48b56ace584426baf1a8a049f5a859c,
title = "Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer",
abstract = "Background: Guidelines recommend sentinel lymph node dissection (SLND) for patients with clinical stage I/IIA/IIB breast cancer; however, a significant fraction of patients do not undergo this procedure. We sought to identify factors associated with noncompliance with the SLND benchmark in early-stage breast cancer. Materials and Methods: All patients with an initial diagnosis of Stage I/IIA/IIB invasive breast carcinoma who were treated between 2004 and 2007 with records in the California Cancer Registry were evaluated. Odds ratios evaluating receipt of SLND were compared for sex, age, stage, socioeconomic status (SES), race/ethnicity, surgery type, year of diagnosis, and hospital cancer program approval from the American College of Surgery (ACOS). Results: Of 55,207 patients identified, 66{\%} underwent SLND. On multivariable analyses, patients were significantly less likely to undergo SLND if they were >65 years of age, stage IIA or IIB, of lower socioeconomic status, of nonwhite race/ethnicity, treated with total mastectomy, treated during 2004-2005, or at a non-ACOS approved institution. Conclusions: SLND use in California has increased over time; however, only two-thirds of eligible patients undergo this recommended procedure. Using SLND as a quality measure demonstrates significant disparities that have implications not only for patient and provider education, but also for health care policy and reform.",
author = "Windy Olaya and Jan Wong and Morgan, {John W.} and Caitlyn Truong and Sharmila Roy-Chowdhury and Kevork Kazanjian and Sharon Lum",
year = "2010",
month = "10",
doi = "10.1245/s10434-010-1248-0",
language = "English (US)",
volume = "17",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer

AU - Olaya, Windy

AU - Wong, Jan

AU - Morgan, John W.

AU - Truong, Caitlyn

AU - Roy-Chowdhury, Sharmila

AU - Kazanjian, Kevork

AU - Lum, Sharon

PY - 2010/10

Y1 - 2010/10

N2 - Background: Guidelines recommend sentinel lymph node dissection (SLND) for patients with clinical stage I/IIA/IIB breast cancer; however, a significant fraction of patients do not undergo this procedure. We sought to identify factors associated with noncompliance with the SLND benchmark in early-stage breast cancer. Materials and Methods: All patients with an initial diagnosis of Stage I/IIA/IIB invasive breast carcinoma who were treated between 2004 and 2007 with records in the California Cancer Registry were evaluated. Odds ratios evaluating receipt of SLND were compared for sex, age, stage, socioeconomic status (SES), race/ethnicity, surgery type, year of diagnosis, and hospital cancer program approval from the American College of Surgery (ACOS). Results: Of 55,207 patients identified, 66% underwent SLND. On multivariable analyses, patients were significantly less likely to undergo SLND if they were >65 years of age, stage IIA or IIB, of lower socioeconomic status, of nonwhite race/ethnicity, treated with total mastectomy, treated during 2004-2005, or at a non-ACOS approved institution. Conclusions: SLND use in California has increased over time; however, only two-thirds of eligible patients undergo this recommended procedure. Using SLND as a quality measure demonstrates significant disparities that have implications not only for patient and provider education, but also for health care policy and reform.

AB - Background: Guidelines recommend sentinel lymph node dissection (SLND) for patients with clinical stage I/IIA/IIB breast cancer; however, a significant fraction of patients do not undergo this procedure. We sought to identify factors associated with noncompliance with the SLND benchmark in early-stage breast cancer. Materials and Methods: All patients with an initial diagnosis of Stage I/IIA/IIB invasive breast carcinoma who were treated between 2004 and 2007 with records in the California Cancer Registry were evaluated. Odds ratios evaluating receipt of SLND were compared for sex, age, stage, socioeconomic status (SES), race/ethnicity, surgery type, year of diagnosis, and hospital cancer program approval from the American College of Surgery (ACOS). Results: Of 55,207 patients identified, 66% underwent SLND. On multivariable analyses, patients were significantly less likely to undergo SLND if they were >65 years of age, stage IIA or IIB, of lower socioeconomic status, of nonwhite race/ethnicity, treated with total mastectomy, treated during 2004-2005, or at a non-ACOS approved institution. Conclusions: SLND use in California has increased over time; however, only two-thirds of eligible patients undergo this recommended procedure. Using SLND as a quality measure demonstrates significant disparities that have implications not only for patient and provider education, but also for health care policy and reform.

UR - http://www.scopus.com/inward/record.url?scp=78149275555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149275555&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1248-0

DO - 10.1245/s10434-010-1248-0

M3 - Article

C2 - 20853050

AN - SCOPUS:78149275555

VL - 17

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - SUPPL. 3

ER -